On February 5, 2020 AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, reported posting by the University of Pittsburgh Medical Center (UPMC) on January 28, 2020 via ClinicalTrials.gov of completion of an independent, third-party clinical trial to evaluate the safety and activity of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and Ampligen (rintatolimod), given with a dendritic cell (DC) vaccine, as a potential treatment for metastatic peritoneal surface malignancies after standard of care surgery (Press release, AIM ImmunoTech, FEB 5, 2020, View Source [SID1234553895]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The principal investigator of the trial was David L. Bartlett, MD, an internationally recognized cancer researcher at UPMC, in collaboration with the National Cancer Institute. Detailed analysis of the clinical data by the investigators is expected to be reported by publication. For more information on the results, including limitations of the clinical trial, which according to the filing saw a median survival rate of 52 months for the 64 patients treated in the study, please visit: View Source
"We were honored to have Ampligen included in this trial and believe the outcome of this trial will be informative given the growing body of evidence supporting the important role Ampligen may play in modulating the immune system in oncology," said AIM ImmunoTech CEO Thomas K. Equels. "Ampligen is a broadly applicable immune therapy that has the potential to be used in a wide range of therapies with a generally well-tolerated safety profile based on approximately 100,000 IV doses in humans to date, as well as Phase 1 safety studies in intraperitoneal (IP) and intranasal (IN) administration. Ampligen is also being studied in six immuno-oncology clinical trials in combination with checkpoint blockade drugs or other immuno-therapies at highly respected NCI-Designated Cancer Centers. We appreciate the strong third-party interest in our platform drug candidate Ampligen."